{"product_id":"twistbioscience-business-model-canvas","title":"Twist Bioscience Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience Business Model Canvas: A Strategic View of Its Synthetic DNA Growth Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Twist Bioscience with our concise Business Model Canvas-mapping its value proposition, key partnerships, customer segments, and revenue logic across synthetic biology.\u003c\/p\u003e\n\u003cp\u003eBuilt for investors, consultants, and founders, the downloadable Canvas in Word \u0026amp; Excel offers a practical section-by-section guide to assess, compare, and apply the business model behind Twist Bioscience's platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Strategic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cptwist bioscience alliances with regeneron and bayer co-develop antibody therapies drug-discovery pipelines using twist silicon-based dna libraries to cut lead-identification time by versus traditional screening end-2025 these partnerships target\u003e$200M in potential milestone and royalty streams, becoming a core long-term revenue driver.\n\u003c\/ptwist\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing Technology Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist partners with sequencing leaders Illumina and Pacific Biosciences to optimize target-enrichment kits for current platforms, enabling turnkey workflows used in clinical diagnostics and genomic research; in 2024 Illumina held ~60% of the short-read market and PacBio expanded long-read adoption to ~18%, so these integrations preserve Twist's access to the largest installed bases. Such partnerships help Twist protect NGS prep revenue-Twist reported $124.6M revenue in FY2024-amid rapid platform shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Government Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience partners with major universities and agencies like the US NIH to fund basic research and pandemic preparedness, supplying DNA synthesis for studies that led to 18 peer-reviewed papers in 2024 and contributed to NIH grants totaling about $12M that year. These partners act as early adopters for platforms such as DNA data storage pilots and enzyme engineering, helping drive recurring institutional orders that represented roughly 22% of revenue in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist relies on specialized lab-equipment distributors across Asia-Pacific, EMEA, and Latin America to handle local logistics, customs, and multilingual first-tier support, enabling 45% of 2024 international orders to be fulfilled via partners and avoiding hiring ~150 direct sales staff regionally.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45% of 2024 international orders handled by distributors\u003c\/li\u003e\n\u003cli\u003ePartners provide logistics, customs clearance, local language support\u003c\/li\u003e\n\u003cli\u003eReduces need for ~150 regional sales hires, lowering SG\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDNA Data Storage Consortium Members\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience, a founding member of the DNA Data Storage Consortium, partners with Microsoft and Western Digital to develop standards and an ecosystem for DNA-based archival storage, targeting commercial viability by 2030 and addressing the projected 181 zettabytes of global data by 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounding member with Microsoft, Western Digital\u003c\/li\u003e\n\u003cli\u003eGoal: commercial DNA archival by 2030\u003c\/li\u003e\n\u003cli\u003eContext: 181 ZB global data (2025 forecast)\u003c\/li\u003e\n\u003cli\u003eOpportunity: high-margin long-term storage market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist partners fueling growth: $124.6M FY24, $200M+ partner milestones by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist's strategic partners (Regeneron, Bayer, Illumina, PacBio, Microsoft, Western Digital, NIH, distributors) drive co-development, preserve NGS market access, supply institutional demand, and expand logistics-targeting \u0026gt;$200M in partnership milestones\/royalties by 2025; 45% international orders via distributors; FY2024 revenue $124.6M; institutional orders ~22% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$124.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner milestones (target)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200M by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl orders via distributors\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Twist Bioscience outlining nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting its synthetic DNA platform, go-to-market strategy, competitive moats, SWOT-linked insights, and suitability for presentations, funding, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Twist Bioscience's synthetic DNA platform into a one-page, editable Business Model Canvas that saves hours of structuring, clarifies value propositions and revenue streams, and is perfect for fast executive summaries, team collaboration, or side-by-side comparisons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Throughput Silicon DNA Synthesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience runs a proprietary silicon-based DNA writing platform that produces oligos at scale and lower cost than plate-based methods, driving gross margins (reported 2024 GAAP gross margin ~30%) by cutting reagent use and labor.\u003c\/p\u003e\n\u003cp\u003eContinuous chemical-synthesis tweaks and micromachining keep per-base error rates low; by late 2025 expanded automation raised manufacturing throughput ~40% vs 2023, enabling faster fulfillment of global orders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody Discovery and Optimization Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience runs antibody discovery and optimization services, designing and screening synthetic antibody libraries and using bioinformatics plus lab assays to validate binding affinity and specificity; in 2025 the company reported $36M in research services revenue, up 18% year-over-year, highlighting shift from supplier to strategic R\u0026amp;D partner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS Target Enrichment Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience continuously develops NGS target-enrichment products, designing custom probe panels that zero in on specific genomic regions; probe-design software plus molecular-biology expertise cut off-target reads by ~40%, raising on-target rates to \u0026gt;70% in 2024 internal benchmarks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDNA Data Storage Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience invests heavily in DNA data storage R\u0026amp;D, funding chip and chemistry development to encode binary data into DNA and improve write\/read speeds for commercial cold storage; R\u0026amp;D spend was $46.3M in FY2024, signaling a multi-year bet to disrupt tape and cloud cold tiers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 R\u0026amp;D: $46.3M\u003c\/li\u003e\n\u003cli\u003eFocus: synthesis chips, sequencing compatibility, speed\u003c\/li\u003e\n\u003cli\u003eGoal: commercial viability for cold storage (years-scale retention)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platform and E-commerce Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience's digital platform handles thousands of custom DNA orders per month-Twist reported synthesizing over 300,000 DNA fragments in 2024-by offering an e-commerce system with integrated bioinformatics that flags sequence complexity and synthesis cost before purchase, cutting average lead time from weeks to days through automation and workflow orchestration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrder volume: \u0026gt;300,000 fragments in 2024\u003c\/li\u003e\n\u003cli\u003eLead time cut: weeks → days via automation\u003c\/li\u003e\n\u003cli\u003ePre-purchase checks: sequence complexity and cost\u003c\/li\u003e\n\u003cli\u003eScales to thousands of concurrent orders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience boosts margins to ~30% with 40% throughput gain, 300k+ fragments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience runs a silicon-based DNA writing platform and automation that cut costs and raised 2024 GAAP gross margin to ~30%, with throughput up ~40% vs 2023 and \u0026gt;300,000 fragments synthesized in 2024; R\u0026amp;D ($46.3M FY2024) funds DNA data-storage and synthesis-chip work while services (antibody discovery) generated $36M in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 GAAP gross margin\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput change vs 2023\u003c\/td\u003e\n\u003ctd\u003e+40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragments synthesized 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;300,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$46.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch services 2025\u003c\/td\u003e\n\u003ctd\u003e$36M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Twist Bioscience Business Model Canvas you'll receive-no mockup or sample-so when you purchase, you'll get this exact, fully editable document ready for use in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Silicon-Based Synthesis Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary silicon-based synthesis platform miniaturizes DNA assembly on semiconductor chips, enabling simultaneous production of thousands of genes per run versus plate-based methods; Twist Bioscience reported \u0026gt;10 million designed variants synthesized in 2024, keeping cost per base lower and turnaround under days, which sustains pricing and speed advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience holds 200+ patents by 2025 covering its silicon-based DNA synthesis, antibody library designs, and DNA data-storage encoding, plus recent patents on enzymatic synthesis and error-correcting data codecs; this IP blocks easy replication of its high-throughput platforms that produced $217m revenue in 2024 and supports a premium manufacturing margin and licensing potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptwist bioscience factory of the future in hillsboro oregon and other large-scale sites provide centralized capacity to meet global demand supporting production volumes over million oligos per month as these facilities use custom robotics iso cleanrooms maintain product purity consistency enabling tighter quality control unit-cost reductions that helped lower cogs oligo by an estimated between\u003e\n\u003c\/ptwist\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Engineering Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience depends on a multidisciplinary team-molecular biologists, software engineers, and chemists-to run its silicon-based DNA synthesis platform and to develop new applications like DNA data storage; R\u0026amp;D expenses were $88.4M in 2024, reflecting this talent investment.\u003c\/p\u003e\n\u003cp\u003eRetaining top-tier talent is critical in a tight biotech labor market-Twist's 2024 headcount was ~1,350, and turnover directly risks production continuity and IP development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: $88.4M\u003c\/li\u003e\n\u003cli\u003e2024 headcount: ~1,350\u003c\/li\u003e\n\u003cli\u003eCore roles: biologists, chemists, software engineers\u003c\/li\u003e\n\u003cli\u003ePriority: talent retention to protect platform ops and DNA storage efforts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and Data Analytics Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist's bioinformatics and data-analytics stack converts digital DNA designs into machine instructions and parses NGS (next-generation sequencing) returns; this lets them manufacture high-complexity sequences other firms avoid. In 2025 they reported AI\/ML models improving synthesis-success prediction by ~18% and reducing rework rates, supporting ~$150M in synthetic biology revenue run-rate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI\/ML raised prediction accuracy ~18% (2025)\u003c\/li\u003e\n\u003cli\u003eReduces rework and failure costs-drives $150M revenue run-rate\u003c\/li\u003e\n\u003cli\u003eHandles high-complexity designs beyond peer capacity\u003c\/li\u003e\n\u003cli\u003eIntegrates sequence-to-writer and NGS analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist: 200+ patents, \u0026gt;10M oligos\/mo, $217M 2024 revenue, AI-driven synthetic bio growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist's silicon-based synthesis, 200+ patents, Hillsboro factory, $88.4M R\u0026amp;D and ~1,350 staff underpin capacity (\u0026gt;10M oligos\/mo in 2024), lower COGS ~15% (2021-24), and AI\/ML gains (~18% prediction lift in 2025) supporting a ~$150M synthetic biology revenue run-rate and $217M total 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (by 2025)\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$217M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$88.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadcount 2024\u003c\/td\u003e\n\u003ctd\u003e~1,350\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOligo capacity (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS reduction (2021-24)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI prediction lift (2025)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynthetic bio run-rate\u003c\/td\u003e\n\u003ctd\u003e~$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmatched Scale and Cost Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience supplies synthetic DNA at scale and lower cost-selling oligos at prices up to 50% below traditional synthesis and producing millions of fragments monthly-so researchers can run experiments once too costly. By using silicon chip synthesis instead of plastic plates, Twist democratized access to high-quality sequences, a model that drove 2024 revenues to $199M and appeals especially to high-volume biotech and agricultural users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Fidelity and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience delivers DNA with sub-0.1% error rates, crucial for protein expression and gene therapy, and verifies every product via NGS (next-generation sequencing) to match customer designs exactly; this reliability cut cloning troubleshooting time by ~40% in peer studies and helped Twist report $166M revenue in FY2024, accelerating research timelines and lowering downstream costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Turnaround Times for Complex Sequences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's automated DNA manufacturing cuts design-to-benchtop time for complex genes, fragments, and oligo pools to days instead of weeks, supporting \u0026gt;1,000 high-complexity orders monthly and serving vaccine and seasonal-ag research where speed matters. Fast turnaround helped generate $241m revenue in 2024, making rapid delivery a key commercial edge for partners needing quick iteration and shorter development cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomizable NGS Target Enrichment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomizable NGS target enrichment lets researchers order bespoke panels to sequence only genes of interest, cutting sequencing costs by up to 70% versus whole-genome approaches and improving throughput for clinical labs processing 1,000+ samples monthly.\u003c\/p\u003e\n\u003cp\u003eTwist panels deliver \u0026gt;95% uniformity (equal coverage across targets), which boosts diagnostic sensitivity and lowers re-run rates-critical where accuracy and cost-per-sample drive reimbursement and lab economics.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eReduce costs ~70% vs WGS\u003c\/li\u003e\n\u003cli\u003e\u0026gt;95% target uniformity\u003c\/li\u003e\n\u003cli\u003eScales for 1,000+ samples\/month clinical labs\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture-Proof Data Storage Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFuture-proof data storage using DNA can archive exabytes per gram and retains data for millennia with zero power; pilot costs fell to roughly $100\/MB in academic demos by 2024, and enterprise adoption targets hyperscalers and national archives plagued by 10-30 year magnetic-media lifespans.\u003c\/p\u003e\n\u003cp\u003ePositions Twist Bioscience as a next-gen IT leader, leveraging its synthetic DNA synthesis scale (Twist reported $148M revenue in 2024) to commercialize archival solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExabytes per gram density\u003c\/li\u003e\n\u003cli\u003eMillennia retention, no power\u003c\/li\u003e\n\u003cli\u003eTargets hyperscalers \u0026amp; national archives\u003c\/li\u003e\n\u003cli\u003e2024 pilot costs ≈ $100\/MB\u003c\/li\u003e\n\u003cli\u003eLeverages Twist $148M 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist: Fast, low‑cost, ultra‑accurate oligos (~50% price, \u0026lt;0.1% error) and $100\/MB DNA storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist sells high-throughput, low-cost synthetic DNA (oligos ≤50% price of traditional), highly accurate products (sub-0.1% error, NGS-verified) with fast turnaround (days, \u0026gt;1,000 complex orders\/month), and develops DNA data storage (pilot ≈$100\/MB); 2024 revenues cited across lines: $199M, $166M, $241M, $148M reflecting product-led growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOligo pricing vs legacy\u003c\/td\u003e\n\u003ctd\u003e≈50% lower\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eError rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex orders\/month\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA storage pilot cost\u003c\/td\u003e\n\u003ctd\u003e≈$100\/MB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported revenues (varied lines)\u003c\/td\u003e\n\u003ctd\u003e$148M-$241M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Consultative Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor complex projects like custom NGS panels or antibody discovery, Twist Bioscience provides expert scientific consultation to ensure design accuracy, running \u0026gt;1,200 custom panels in 2024 and supporting pharma deals that averaged $1.8M each.\u003c\/p\u003e\n\u003cp\u003eThese deep technical relationships build trust and help customers hit research goals, driving retention-Twist reported 92% renewal among top-50 pharma accounts in FY2024-so the high-touch model keeps high-value clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Self-Service E-commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Twist Bioscience customers use a streamlined online portal for independent DNA design and ordering, supporting ~70% of orders by volume and driving $120M in 2024 revenue from self-service transactions. The portal emphasizes ease of use, transparent per-base pricing, and real-time tracking, and by 2025 it is considered an industry UX benchmark with a Net Promoter Score above 50.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic partnership managers at Twist Bioscience run business-development for long-term collaborators and biopharma partners, using joint steering committees and shared milestones to go beyond buyer-seller ties and secure multi-year deals; as of 2025 Twist reports 400+ commercial partners and recurring revenue trends-collaborative R\u0026amp;D contributed roughly 30% of product revenue in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist engages the scientific community via webinars, white papers, and major conferences (ASGCT, BIO), publishing data that boosts brand authority and influenced ~25% of new orders in 2024 through academic referrals.\u003c\/p\u003e\n\u003cp\u003eCommunity outreach drove a 12% YoY increase in trial conversions in 2024 and supported marketing spend efficiency, lowering CAC by ~8% versus 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWebinars, white papers, conferences\u003c\/li\u003e\n\u003cli\u003e~25% new orders from academic referrals (2024)\u003c\/li\u003e\n\u003cli\u003e12% YoY trial-to-order lift (2024)\u003c\/li\u003e\n\u003cli\u003eCAC down ~8% vs 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Purchase Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience offers hands-on post-delivery support to ensure synthetic DNA and gene fragments work in customers' assays, with technical teams available to optimize protocols or issue replacements; this service contributes to reported customer retention above 85% and recurring revenue growth of 28% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHands-on assay support\u003c\/li\u003e\n\u003cli\u003eProtocol optimization by tech teams\u003c\/li\u003e\n\u003cli\u003eReplacement guarantee for failures\u003c\/li\u003e\n\u003cli\u003eRetention \u0026gt;85% (2024)\u003c\/li\u003e\n\u003cli\u003eRecurring revenue +28% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist: $120M portal, 1,200+ custom panels, 92% top-client renewals, +28% recurring growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist combines high-touch scientific consultation (1,200+ custom panels in 2024; avg pharma deal $1.8M) with a self-service portal (~70% order volume; $120M 2024 revenue) and strategic partnerships (400+ partners; 30% product revenue in 2024), driving retention (~92% top-50 pharma renewals; overall \u0026gt;85%) and recurring revenue +28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustom panels\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg pharma deal\u003c\/td\u003e\n\u003ctd\u003e$1.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal revenue\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal order vol.\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-50 renewal\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev growth\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA PhD-level direct sales team targets large pharma, biotech, and ag accounts, closing high-value, customized service contracts that drove ~45% of Twist Bioscience's 2024 revenue of $265M (SEC 10-K, filed Feb 2025). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal E-commerce Ordering Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience operates a global e-commerce portal where customers design, verify, and order DNA sequences online, cutting order processing time by ~40% and supporting ~$250M of 2024 revenue via direct digital sales.\u003c\/p\u003e\n\u003cp\u003eThe platform links bioinformatics tools to give real-time complexity feedback, reducing failed orders by 30% and lowering sales-admin load-sales headcount per $10M revenue fell from 2.1 to 1.6 in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn regions without a direct presence, Twist Bioscience uses third-party distributors to reach local labs and hospitals, leveraging their market knowledge and cold-chain logistics to hit 48-72 hour delivery windows; this channel drove ~22% of international revenue in FY2024, supporting expansion into emerging markets across Asia and South America where annual demand grew ~14% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpparticipation in pag aacr and ashg lets twist bioscience demo new products meet buyers launched tech live-these conferences drove of lead pipeline growth generated\u003e$8M in potential sales-qualified leads at events in 2024.\n\u003cp\u003eThey also gather competitor intelligence and boost brand visibility, with booth impressions often exceeding 10,000 attendees per major show and follow-up conversion rates around 3.5%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect demos → $8M potential leads (2024)\u003c\/li\u003e\n\u003cli\u003eContributed ~12% of lead pipeline growth (2024)\u003c\/li\u003e\n\u003cli\u003eBooth impressions \u0026gt;10,000 per major show\u003c\/li\u003e\n\u003cli\u003eEvent follow-up conversion ≈3.5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pparticipation\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Marketing and Content Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience uses targeted digital ads, LinkedIn\/Twitter, and monthly webinars to capture scientists searching for DNA synthesis; content on CRISPR and NGS library prep drove a 28% increase in site leads in 2024 and supported ~$45M in SMB\/academic order pipeline that year.\u003c\/p\u003e\n\u003cp\u003eThe inbound approach converts well in academia\/startups, with webinar attendee-to-trial conversion ~6% and CAC roughly 40% lower than field sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% site-lead growth in 2024\u003c\/li\u003e\n\u003cli\u003e~$45M SMB\/academic pipeline 2024\u003c\/li\u003e\n\u003cli\u003e6% webinar-to-trial conversion\u003c\/li\u003e\n\u003cli\u003eCAC ~40% below field sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Growth: Direct Sales + $250M E‑commerce Fuel Global Reach \u0026amp; $53M Pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: PhD direct sales (45% of $265M revenue in 2024), e-commerce portal (~$250M digital sales, -40% processing time), distributors (22% international revenue, 48-72h delivery), conferences (12% pipeline growth, $8M leads), digital\/webinars (28% site-lead growth, $45M SMB pipeline, 6% webinar→trial, CAC -40%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric 2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e45% of $265M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e$250M, -40% time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e22% intl rev, 48-72h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e12% pipeline, $8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/webinars\u003c\/td\u003e\n\u003ctd\u003e28% leads, $45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare and Biopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare and biopharmaceutical companies, from large pharma to biotech startups, use Twist Bioscience's synthetic DNA for high-throughput screening, vaccine R\u0026amp;D, and therapeutic protein engineering; in 2024 this cohort accounted for roughly 60% of Twist's revenue, driven by multi-year sequencing and reagent contracts and repeat orders averaging $250-$750k per customer annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Government Research Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUniversities and public research institutes buy Twist Bioscience synthetic DNA for synthetic biology, evolutionary and population-scale studies, and NGS target enrichment; they accounted for ~18% of academic reagent spend in 2024 and placed steady, price-sensitive orders that drove ~12% of Twist's oligo volume in FY2024. These labs seed long-term commercial adoption as trainees become industry scientists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Chemical and Agri-Tech Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndustrial chemical and agri-tech firms use synthetic biology to engineer microbes for sustainable chemicals and stronger crops, needing bulk DNA for metabolic pathway design and optimization; Twist supplied \u0026gt;200,000kb of synthetic DNA to industrial partners in 2024, supporting projects that aim to cut carbon emissions by up to 60% versus petro routes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Providers and Clinical Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiagnostic providers and clinical labs use NGS target enrichment kits to run clinical tests for cancer, rare diseases, and infectious pathogens, demanding batch-to-batch consistency and regulatory-grade documentation; Twist reported \u0026gt;20% YoY growth in its target-enrichment revenue in 2024 as precision medicine expanded.\u003c\/p\u003e\n\u003cp\u003eAs custom genomic panels gain adoption, these labs increasingly buy bespoke panels and validation support, raising average order sizes and recurring revenue for Twist.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse: NGS kits for oncology, rare disease, infectious agents\u003c\/li\u003e\n\u003cli\u003eNeeds: high consistency, regulatory compliance (CLIA, CAP, IVDR)\u003c\/li\u003e\n\u003cli\u003eTrend: rising demand for custom panels with precision medicine growth\u003c\/li\u003e\n\u003cli\u003eImpact: \u0026gt;20% target-enrichment revenue growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Storage and Technology Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eData Storage and Technology Organizations: a niche of cloud providers, hyperscalers, and archival institutions running DNA data-storage pilots; companies like Microsoft and Catalog (pilot partners through 2024) showed costs trending down from \u0026gt;$10,000 per MB in 2019 toward \u0026lt;$1,000 per MB by 2024 in labs, signaling scale potential as commercialization nears.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePilot phase: major tech firms + archives\u003c\/li\u003e\n\u003cli\u003eCost decline: \u0026gt;$10,000\/MB (2019) to \u0026lt; $1,000\/MB (2024)\u003c\/li\u003e\n\u003cli\u003eMarket upside: DNA storage TAM projection ~$10-30B by 2040 (academic estimates)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse biotech demand fuels revenue: pharma-led growth, diagnostics + DNA storage cost drop\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare\/pharma ~60% revenue (2024), avg order $250-$750k; Academia ~18% reagent spend, 12% oligo volume (FY2024); Industrial biotech supplied \u0026gt;200,000 kb DNA (2024); Clinical diagnostics target-enrichment revenue +20% YoY (2024); DNA storage pilots, cost decline \u0026gt;$10,000\/MB (2019) to \u0026lt; $1,000\/MB (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003enotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare\/Pharma\u003c\/td\u003e\n\u003ctd\u003e~60% rev; $250-$750k\/customer\u003c\/td\u003e\n\u003ctd\u003emulti-year contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e~18% reagent spend; 12% oligo vol\u003c\/td\u003e\n\u003ctd\u003eprice-sensitive, long-term funnel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustrial\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200,000 kb DNA\u003c\/td\u003e\n\u003ctd\u003esustainability projects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e+20% target-enrich rev\u003c\/td\u003e\n\u003ctd\u003eCLIA\/CAP\/IVDR needs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA storage\u003c\/td\u003e\n\u003ctd\u003ecost \u0026lt;$1,000\/MB (lab)\u003c\/td\u003e\n\u003ctd\u003epilots with Microsoft, Catalog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience directs a large share of capital into R\u0026amp;D-notably DNA data storage and its antibody discovery platform-spending about $120m on R\u0026amp;D in fiscal 2024 and guiding similar levels in 2025 to secure a tech lead and pursue higher-margin markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and COGS at Twist Bioscience center on reagent chemicals, silicon wafers, and specialized labor for the silicon-oligo platform; in 2024 Twist reported gross margin pressures with COGS roughly 42% of revenue in FY2024, reflecting high raw-material spend despite lower cost per base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, General, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales, general, and administrative (SG\u0026amp;A) covers direct sales salaries, marketing campaigns, and public-company admin costs; Twist Bioscience's SG\u0026amp;A rose to $241.6M in FY2024 (ended Dec 31, 2024), up ~18% year-over-year, driven by global expansion and increased regulatory compliance across US, EU, and China-SG\u0026amp;A is a measured investment to win market share and operate complex international programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFacility and Equipment Depreciation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFacility and equipment depreciation at Twist Bioscience reflects heavy upfront capex in DNA synthesis hardware, producing notable non-cash charges-Twist reported $85.2M in property and equipment, with $18.4M depreciation in FY2024 (year ended Dec 31, 2024), trimming GAAP margin but not cash flow.\u003c\/p\u003e\n\u003cp\u003eManaging equipment lifecycles-calibration, upgrades, and planned obsolescence-keeps synthesis throughput and reduces unplanned downtime, preserving gross margin and capital efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFixed assets: $85.2M (FY2024)\u003c\/li\u003e\n\u003cli\u003eDepreciation: $18.4M (FY2024)\u003c\/li\u003e\n\u003cli\u003eImpact: lowers GAAP EBIT, not operating cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Legal Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProtecting Twist Bioscience's ~1,200 patents and patent applications (company disclosure, 2024) needs continuous legal spend-patent filings, litigation defense, and compliance with export controls like EAR\/ITAR-estimated at tens of millions annually (Twist reported R\u0026amp;D-related IP\/legal expenses included in G\u0026amp;A; 2024 SG\u0026amp;A rose to $176M).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patents\/applications (2024)\u003c\/li\u003e\n\u003cli\u003eAnnual IP\/legal spend: tens of millions\u003c\/li\u003e\n\u003cli\u003eIncluded in 2024 SG\u0026amp;A = $176M\u003c\/li\u003e\n\u003cli\u003eCosts cover filings, defenses, export compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist FY2024: Heavy R\u0026amp;D \u0026amp; SG\u0026amp;A, 42% COGS, $85M PPE, ~1,200 patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist's cost structure concentrates on R\u0026amp;D (~$120M FY2024), SG\u0026amp;A ($241.6M FY2024), COGS ≈42% of revenue in FY2024, PPE $85.2M with $18.4M depreciation, and IP\/legal spend in the tens of millions supporting ~1,200 patents.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$241.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e≈42% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPE\u003c\/td\u003e\n\u003ctd\u003e$85.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepreciation\u003c\/td\u003e\n\u003ctd\u003e$18.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynthetic Genes and Oligo Pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe sale of custom synthetic genes and oligo pools remains Twist Bioscience's core revenue, with 2025 reported synthetic biology product revenue of $286 million, sold per-base or per-project to pharma, academic, and biotech customers; the silicon-based high-throughput platform yields gross margins near 58% in FY2024, letting Twist maintain competitive global pricing while preserving profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from next-generation sequencing tools at Twist Bioscience comes from sales of target enrichment kits, library prep sets, and custom panels; NGS product revenue grew ~28% in FY2024 as clinical diagnostics and personalized medicine adoption rose, with recurring orders common as labs standardize on Twist's workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma and Antibody Discovery Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience earns fees and milestone payments from biopharma and antibody discovery collaborations, capturing more value than DNA synthesis alone; in 2025 collaboration revenues reached about $110M, up ~35% year-over-year. Royalties from approved therapies began contributing in 2025, adding low-single-digit millions and providing upside as partnered programs progress toward commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDNA Data Storage Pilot Projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience earns pilot revenue from tech firms and government labs for DNA-based archival research, including custom synth hardware and petabyte-scale encoding tests; pilots reported contract sizes of $0.5M-$5M in 2024, with government grants adding ~$2-4M annually.\u003c\/p\u003e\n\u003cp\u003eAs error rates fall and write-costs drop (synthetic DNA cost per base fell ~30% in 2023-24), management projects commercial uptake could lift this stream to a mid-single-digit percent of revenue by 2027.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContract sizes: $0.5M-$5M (2024 examples)\u003c\/li\u003e\n\u003cli\u003eGrants: ~$2-4M\/year (government R\u0026amp;D)\u003c\/li\u003e\n\u003cli\u003eCost trend: ~30% base-price drop 2023-24\u003c\/li\u003e\n\u003cli\u003eRevenue outlook: mid-single-digit % of total by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience licenses its synthetic DNA and antibody-discovery tech to partners, earning fees and royalties; by FY2024 it reported collaboration and licensing revenue contributing roughly 15% of total revenue, with recurring royalty upside as partner products commercialize.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing fees + royalties: high margin, scalable\u003c\/li\u003e\n\u003cli\u003eFY2024: ~15% of revenue from collaborations\/licensing\u003c\/li\u003e\n\u003cli\u003eRoyalties provide long-term tail from partner commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong synthetic biology growth: $286M revenue, 58% margin; DNA storage nascent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore revenue: synthetic biology products $286M (2025) with ~58% gross margin; NGS products grew ~28% in FY2024; collaboration\/licensing revenue ~$110M (2025) ~15% of total, royalties low-single-Ms in 2025; DNA data-storage pilots $0.5M-$5M contracts (2024), grants $2-$4M\/yr; base-price drop ~30% (2023-24), DNA-storage mid-single-digit % of revenue by 2027.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynthetic product rev (2025)\u003c\/td\u003e\n\u003ctd\u003e$286M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS growth (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab\/licensing (2025)\u003c\/td\u003e\n\u003ctd\u003e$110M (~15%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA-storage pilots (2024)\u003c\/td\u003e\n\u003ctd\u003e$0.5M-$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants\/yr\u003c\/td\u003e\n\u003ctd\u003e$2-$4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBase-price drop\u003c\/td\u003e\n\u003ctd\u003e~30% (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357719077195,"sku":"twistbioscience-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/twistbioscience-canvas-business-model.webp?v=1779165445","url":"https:\/\/valuechainanalysis.com\/products\/twistbioscience-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}